2122
J. Am. Chem. Soc. 2000, 122, 2122-2123
configurations of (+)-madindoline A (1) and (-)-madindoline B
(2), the latter the enantiomer of natural madindoline B (vide infra).
As prelude to total synthesis, we devised an efficient, asym-
metric synthesis of the 3a-hydroxyfuroindoline ring system.6 On
the basis of our observation that m-CPBA oxidation of tryptophol
(3) furnished 3a-hydroxyfuroindoline (4) in 75% yield, we
explored the Sharpless asymmetric epoxidation protocol.7 Sto-
ichiometric oxidation [2.5 equiv t-BuOOH, 1.2 equiv (+)-DIPT,
1.0 equiv Ti(Oi-Pr)4, CH2Cl2 (0.01 M)] for 6 h at -20 °C led to
(-)-48 in 72% yield and 99% ee (Scheme 1); catalytic protocols
proved less effective (e.g., 37% yield; 28% ee). The absolute
configuration of (-)-4 (3aR,8aS), determined by single-crystal
X-ray analysis of the N-methyl-O-MTPA ester, proved consistent
with the Sharpless epoxidation mnemonic.7
Total Synthesis of (+)-Madindoline A and
(-)-Madindoline B, Potent, Selective Inhibitors of
Interleukin 6. Determination of the Relative and
Absolute Configurations
Toshiaki Sunazuka, Tomoyasu Hirose, Tatsuya Shirahata,
Yoshihiro Harigaya, Masahiko Hayashi,
Kanki Komiyama, and Satoshi Ohmura*
Research Center for Biological Function
The Kitasato Institute
and School of Pharmaceutical Sciences
Kitasato UniVersity, Minato-ku, Tokyo 108, Japan
Amos B. Smith, III*
Department of Chemistry
Laboratory for Research on the Structure of Matter
Monell Chemical Senses Center
Scheme 1
UniVersity of PennsylVania, Philadelphia, PennsylVania 19104
ReceiVed October 26, 1999
Interleukin 6 (IL-6), a multifunctional cytokine, plays a central
regulatory role in host defense mechanisms.1 However, in tumor
cells IL-6 stimulates cell proliferation in an autocrine/paracrine
manner and is responsible for much of the metabolic change
known as cancer cachexia.2 Control of IL-6 activity thus holds
great promise both for the suppression of IL-6-dependent tumor
cell growth and for the relief of cancer cachexia.3
In our program to discover new IL-6 modulators, we recently
reported the isolation and planar structures of (+)-madindolines
A and B (1 and 2),4 novel antibiotics comprised of a 3a-
hydroxyfuroindoline ring connected at nitrogen via a methylene
bridge to a cyclopentene-1,3-dione ring. Structural assignments
were based on extensive 1- and 2-D NMR studies, in conjunction
with IR, UV, and MS data; the relative and absolute configura-
tions, however, remained undefined. Bioassays revealed potent,
selective inhibition of IL-6 activity in the IL-6-dependent cell
line MH60; importantly the response was dose-dependent.4 In
addition, (+)-madindoline A (1), the more potent congener,
inhibited the differentiation of osteoblast cells.4 Preliminary studies
suggest that 1 interacts with the IL-6 receptor.5 Unfortunately,
the original source, Streptomyces nitrosporeus K93-0711, no
longer produces these antibiotics.5
Having secured a viable asymmetric protocol to access the 3a-
hydroxyfuroindoline ring, we envisioned the total synthesis of 1
and 2 to entail reductive coupling of aldehyde 6 (Scheme 2) with
tryptophol (3), followed by the stereocontrolled introduction of
the 3a-hydroxyfuroindoline ring, exploiting the Sharpless protocol.
Aldehyde 6 in turn would derive from 8, the product of a ring-
closing metathesis reaction9 on diene 7, followed by conjugate
introduction of an n-butyl group and oxidation state adjustments.
Diene 7 required for ring metathesis would be constructed
beginning with an initial Evans asymmetric aldol10 on acrolein
Scheme 2
Intrigued by the novel architecture, the significant IL-6
inhibitory activity, and the scarcity of these natural products, we
recently undertook their total synthesis. Herein we report the first
total synthesis and assignment of the relative and absolute
(1) Richards, C. D. In Cytokines; Mire-Sluis, A. R., Thorpe, R., Eds.;
Academic: San Diego, CA, 1998; pp 87-108. Hirano, T. Int. ReV. Immunol.
1998, 16, 249-284 and references therein.
(6) Racemic 3a-hydroxyfuroindoline (()-4 had been prepared previously
by photosensitized oxygenation of tryptophol (3), see: Saito, I.; Imuta, M.;
Nakada, A.; Matsugo, S.; Matsuura, T. Photochem. Photobiol. 1978, 28, 531
and references therein.
(2) Strassmann, G.; Masui, Y.; Chizzoniti, R.; Fong, M. J. Immunology
1993, 150, 2341-2345 and references therein.
(3) Stein, B.; Kung Sutherland, M. S. Drug DiscoVery Today 1998, 3, 202.
(4) (a) Hayashi, M.; Kim, Y.-P.; Takamatsu, S.; Enomoto, A.; Shinose,
M.; Takahashi, Y.; Tanaka, H.; Komiyama, K.; Ohmura, S. J. Antibiot. 1996,
49, 1091. (b) Takamatsu, S.; Kim, Y.-P.; Enomoto, A.; Hayashi, M.; Tanaka,
H.; Komiyama, K.; Ohmura, S. J. Antibiot. 1997, 50, 1069.
(5) Hayashi, M., unpublished results.
(7) Katsuki, T.; Sharpless, K. B. J. Am. Chem. Soc. 1980, 102, 5976.
(8) The structural assignment to each new compound is in accord with its
1
IR, H, and 13C, and high-resolution mass spectra.
(9) For recent reviews, see: (a) Grubbs, R. H.; Chang, S. Tetrahedron 1998,
54, 4413. (b) Armstrong, S. K. J. Chem. Soc., Perkin Trans. 1 1998, 371.
10.1021/ja9938074 CCC: $19.00 © 2000 American Chemical Society
Published on Web 02/17/2000